Amneal Pharmaceuticals, Inc.AMRXEarnings & Financial Report
Amneal Pharmaceuticals, Inc. is an American publicly traded pharmaceutical company that develops, manufactures and distributes generics and specialty pharmaceutical products. The company is headquartered in Bridgewater, New Jersey, and is one of the largest manufacturers of generic drugs in the United States.
AMRX Q1 FY2026 Key Financial Metrics
Revenue
$722.5M
Gross Profit
$320.1M
Operating Profit
$141.8M
Net Profit
$78.0M
Gross Margin
44.3%
Operating Margin
19.6%
Net Margin
10.8%
YoY Growth
3.9%
EPS
$0.19
Amneal Pharmaceuticals, Inc. Q1 FY2026 Financial Summary
Amneal Pharmaceuticals, Inc. reported revenue of $722.5M (up 3.9% YoY) for Q1 FY2026, with a net profit of $78.0M (up 410.5% YoY) (10.8% margin). Cost of goods sold was $402.4M, operating expenses totaled $178.3M.
Key Financial Metrics
| Total Revenue | $722.5M |
|---|---|
| Net Profit | $78.0M |
| Gross Margin | 44.3% |
| Operating Margin | 19.6% |
| Report Period | Q1 FY2026 |
Amneal Pharmaceuticals, Inc. Annual Revenue by Year
Amneal Pharmaceuticals, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $3.0B).
Amneal Pharmaceuticals, Inc. Quarterly Revenue & Net Profit History
Amneal Pharmaceuticals, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $722.5M | +3.9% | $78.0M | 10.8% |
| Q4 FY2025 | $814.3M | +11.5% | $35.1M | 4.3% |
| Q3 FY2025 | $784.5M | +11.7% | $2.4M | 0.3% |
| Q2 FY2025 | $724.5M | +3.2% | $22.4M | 3.1% |
| Q1 FY2025 | $695.4M | +5.5% | $12.2M | 1.8% |
| Q4 FY2024 | $730.5M | +18.4% | $-31.1M | -4.3% |
| Q3 FY2024 | $702.5M | +13.3% | $-156.0K | -0.0% |
| Q2 FY2024 | $701.8M | +17.1% | $6.0M | 0.9% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $701.8M | $702.5M | $730.5M | $695.4M | $724.5M | $784.5M | $814.3M | $722.5M |
| YoY Growth | 17.1% | 13.3% | 18.4% | 5.5% | 3.2% | 11.7% | 11.5% | 3.9% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $3.51B | $3.46B | $3.50B | $3.37B | $3.42B | $3.60B | $3.68B | $3.54B |
| Liabilities | $3.57B | $3.55B | $3.61B | $3.50B | $3.53B | $3.71B | $3.75B | N/A |
| Equity | $-57.5M | $-93.4M | $-109.3M | $-131.7M | $-112.1M | $-109.5M | $-70.8M | N/A |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $39.7M | $141.8M | $118.1M | $7.4M | $83.8M | $118.5M | $130.3M |